Literature DB >> 21121796

Leksell GammaPlan version 10.0 preview: performance of the new inverse treatment planning algorithm applied to Gamma Knife surgery for pituitary adenoma.

David J Schlesinger1, Faisal T Sayer, Chun-Po Yen, Jason P Sheehan.   

Abstract

OBJECT: Treatment planning for Gamma Knife surgery has traditionally been a forward planning (FP)-only approach with results that depend significantly on the experience of the user. Leksell GammaPlan version 10.0, currently in beta testing, introduces a new inverse planning (IP) engine that may allow more reproducible results across dosimetrists and individual institutions. In this study the authors compared the FP and IP approaches to Gamma Knife surgery.
METHODS: Forty-three patients with pituitary adenomas were evaluated after dose planning was performed using FP and IP treatment approaches. Treatment plans were compared for target coverage, target selectivity, Paddick gradient index, number of isocenters, optic pathways dose, and treatment time. Differences between the forward and inverse treatment plans were evaluated in a statistical fashion.
RESULTS: The IP software generated a dose plan within approximately 10 minutes. The FP approach delivered the prescribed isodose to a larger treatment volume than the IP system (p < 0.001). The mean (± SD) FP and IP coverage indices were 0.85 ± 0.23 and 0.85 ± 0.13, respectively (no significant difference). The mean FP and IP gradient indices were 2.78 ± 0.20 and 3.08 ± 0.37, respectively (p < 0.001). The number of isocenters did not appreciably differ between approaches. The maximum doses directed to the optic apparatus for the FP and IP methods were 8.67 ± 1.97 Gy and 12.33 ± 5.86 Gy, respectively (p < 0.001).
CONCLUSIONS: The Leksell GammaPlan IP system was easy to operate and provided a reasonable, first approximation dose plan. Particularly in cases in which there are eloquent structures at risk, experience and user-based optimization will be required to achieve an acceptable Gamma Knife dose plan.

Entities:  

Mesh:

Year:  2010        PMID: 21121796     DOI: 10.3171/2010.7.GKS101033

Source DB:  PubMed          Journal:  J Neurosurg        ISSN: 0022-3085            Impact factor:   5.115


  7 in total

1.  Improved Dose Conformity for Adjacent Targets: A Novel Planning Technique for Gamma Knife Stereotactic Radiosurgery.

Authors:  Qianyi Xu; Jinyu Xue; Gregory Kubicek; David Mulvihill; Steven Oh; Warren Goldman; Alan Turtz; Leonard Kim
Journal:  Cureus       Date:  2018-07-27

2.  Feasibility of identification of gamma knife planning strategies by identification of pareto optimal gamma knife plans.

Authors:  C A Giller
Journal:  Technol Cancer Res Treat       Date:  2011-12

3.  Introduction to passive electron intensity modulation.

Authors:  Kenneth R Hogstrom; Robert L Carver; Erin L Chambers; Kevin Erhart
Journal:  J Appl Clin Med Phys       Date:  2017-09-06       Impact factor: 2.102

4.  Fractionated SRT using VMAT and Gamma Knife for brain metastases and gliomas--a planning study.

Authors:  Marie Huss; Pierre Barsoum; Ernest Dodoo; Georges Sinclair; Iuliana Toma-Dasu
Journal:  J Appl Clin Med Phys       Date:  2015-11-08       Impact factor: 2.102

5.  Clinical Evaluation of the Inverse Planning System Utilized in Gamma Knife Lightning.

Authors:  Taoran Cui; Ke Nie; Jiahua Zhu; Shabbar Danish; Joseph Weiner; Anupama Chundury; Nisha Ohri; Yin Zhang; Irina Vergalasova; Ning Yue; Xiao Wang
Journal:  Front Oncol       Date:  2022-02-23       Impact factor: 6.244

6.  Clinical validation of novel lightning dose optimizer for gamma knife radiosurgery of irregular-shaped arteriovenous malformations and pituitary adenomas.

Authors:  Damodar Pokhrel; Mark E Bernard; James Knight; William St Clair; Justin F Fraser
Journal:  J Appl Clin Med Phys       Date:  2022-06-24       Impact factor: 2.243

7.  IntuitivePlan inverse planning performance evaluation for Gamma Knife radiosurgery of AVMs.

Authors:  Ian Paddick; Diana Grishchuk; Alexis Dimitriadis
Journal:  J Appl Clin Med Phys       Date:  2020-08-04       Impact factor: 2.102

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.